Parallax Volatility Advisers’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-85
| Closed | -$1.83K | – | 1811 |
|
|
2025
Q4 | $1.83K | Hold |
85
| – | – | ﹤0.01% | 1580 |
|
|
2025
Q3 | $1.64K | Buy |
+85
| New | +$1.51K | ﹤0.01% | 1549 |
|
|
2025
Q2 | – | Sell |
-14,416
| Closed | -$615K | – | 1796 |
|
|
2025
Q1 | $920K | Buy |
+14,416
| New | +$1.52M | ﹤0.01% | 1077 |
|
|
2023
Q4 | – | Sell |
-468
| Closed | -$44.9K | – | 2474 |
|
|
2023
Q3 | $56.7K | Buy |
+468
| New | +$52.9K | ﹤0.01% | 2001 |
|
|
2022
Q3 | – | Sell |
-4,631
| Closed | -$467K | – | 3345 |
|
|
2022
Q2 | $347K | Buy |
4,631
+1,292
| +39% | +$95K | ﹤0.01% | 2042 |
|
|
2022
Q1 | $261K | Buy |
+3,339
| New | +$256K | ﹤0.01% | 2099 |
|
|
2021
Q4 | – | Sell |
-2,202
| Closed | -$188K | – | 3442 |
|
|
2021
Q3 | $204K | Buy |
+2,202
| New | +$170K | ﹤0.01% | 2499 |
|
|
2021
Q2 | – | Sell |
-11,861
| Closed | -$899K | – | 3526 |
|
|
2021
Q1 | $884K | Sell |
11,861
-14,224
| -55% | -$1.31M | ﹤0.01% | 2136 |
|
|
2020
Q4 | $4.45M | Buy |
26,085
+22,574
| +643% | +$3.34M | ﹤0.01% | 1481 |
|
|
2020
Q3 | $493K | Buy |
+3,511
| New | +$534K | ﹤0.01% | 2256 |
|
|
2020
Q2 | – | Sell |
-6,997
| Closed | -$952K | – | 2862 |
|
|
2020
Q1 | $684K | Sell |
6,997
-20,118
| -74% | -$2.3M | ﹤0.01% | 1607 |
|
|
2019
Q4 | $3.5M | Buy |
27,115
+22,328
| +466% | +$2.25M | ﹤0.01% | 1042 |
|
|
2019
Q3 | $361K | Sell |
4,787
-8,381
| -64% | -$990K | ﹤0.01% | 1701 |
|
|
2019
Q2 | $2M | Buy |
13,168
+10,533
| +400% | +$1.28M | ﹤0.01% | 1039 |
|
|
2019
Q1 | $314K | Buy |
+2,635
| New | +$339K | ﹤0.01% | 1696 |
|
|
2018
Q3 | – | Sell |
-10,767
| Closed | -$1.47M | – | 3527 |
|
|
2018
Q2 | $1.42M | Buy |
+10,767
| New | +$1.02M | ﹤0.01% | 1004 |
|
|
2018
Q1 | – | Sell |
-13,907
| Closed | -$927K | – | 4068 |
|
|
2017
Q4 | $774K | Buy |
13,907
+8,623
| +163% | +$457K | ﹤0.01% | 1293 |
|
|
2017
Q3 | $240K | Buy |
+5,284
| New | +$211K | ﹤0.01% | 1428 |
|
|
2017
Q2 | – | Sell |
-9,813
| Closed | -$320K | – | 3848 |
|
|
2017
Q1 | $290K | Buy |
+9,813
| New | +$304K | ﹤0.01% | 1785 |
|
|
2016
Q4 | – | Sell |
-27,349
| Closed | -$1.1M | – | 4092 |
|
|
2016
Q3 | $1.68M | Buy |
+27,349
| New | +$827K | ﹤0.01% | 1060 |
|
Other funds holding SRPT
RCM
EAM
Parallax Volatility Advisers's SRPT Position: Q1 2026 in Review
Parallax Volatility Advisers sold out of Sarepta Therapeutics (SRPT) in Q1 2026, closing a stake of 85 shares — an estimated $1.83K sold.
Parallax Volatility Advisers first reported a position in SRPT in Q3 2016 and held it in 20 quarters. The position peaked at $4.45M in Q4 2020. 344 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.
- Parallax Volatility Advisers reported no remaining Sarepta Therapeutics position as of Q1 2026 after selling out during the quarter.
- Parallax Volatility Advisers sold 85 Sarepta Therapeutics shares in Q1 2026, an estimated $1.83K.
- Parallax Volatility Advisers first reported a position in Sarepta Therapeutics in Q3 2016 and held it in 20 quarters.
- Parallax Volatility Advisers's Sarepta Therapeutics position peaked at $4.45M in Q4 2020.
- 344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.
Based on Parallax Volatility Advisers's 13F filing for Q1 2026, filed 15 May 2026.